Latest / Community Health Media
Dr. Nusayba Bagegni & Dr. Philip Lammers - Targeting & Sequencing Endocrine Pathways After CDK4/6i
What is the optimal treatment strategy after progression on a CDK4/6 inhibitor in HR-positive, HER2-negative metastatic breast cancer?
Dr. Nusayba Bagegni and Dr. Philip Lammers discuss how they approach treatment sequencing in an increasingly complex landscape that now includes AKT inhibitors, oral SERDs, PROTACs, ADCs, and ctDNA-guided decision making. The conversation explores the role of tumor biology, molecular testing, PI3K/AKT/PTEN pathway alterations, ESR1 mutations, and how clinicians balance efficacy, toxicity, and quality of life when selecting second-line and later-line therapies…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.